Paradigm Hits 50% Dosing in Phase 3 Osteoarthritis Trial Ahead of Aug 2026 Read
Paradigm Biopharmaceuticals (ASX: PAR) has dosed 50% of participants in its global Phase 3 trial evaluating injectable pentosan polysulfate sodium (iPPS) for knee osteoarthritis, positioning the late-stage biotech firm on track for interim analysis results in August 2026. The PARAOA012 study has enrolled patients across Australia, the United States, Europe and Asia, with the final participants required for the interim dataset now commenced on treatment.
Paradigm reaches 50% dosing milestone in Phase 3 osteoarthritis trial
The 50% dosing milestone represents significant progress toward the interim analysis, a critical inflection point that will provide the first Phase 3 efficacy readout for investors. Participants are followed through a Day 112 assessment period, after which the interim dataset undergoes data cleaning and independent data monitoring committee (DMC) statistical analysis over approximately four to six weeks.
The PARAOA012 study is designed to enrol 466 participants globally, with patients randomised to receive iPPS or placebo. The primary endpoint is the change in weekly average of daily pain at Day 112, with secondary endpoints including improvements in physical function, imaging-based structural outcomes, and safety assessments.
Patient recruitment continues across Paradigm’s global network of clinical trial sites, with progression toward 100% enrolment expected in the coming months. The trial remains on track consistent with the company’s previously announced time schedule.
When big ASX news breaks, our subscribers know first
What is osteoarthritis and why does it need new treatments?
Osteoarthritis is a degenerative joint condition causing pain, stiffness and disability as protective cartilage cushioning the ends of bones gradually wears down. The condition affects more than 500 million people globally and remains one of the leading causes of disability worldwide.
Despite the size of the market, there are currently no widely approved disease-modifying treatments for osteoarthritis. Most existing therapies focus only on symptom management rather than addressing the underlying disease mechanisms. This creates a significant unmet medical need.
Paradigm’s injectable PPS programme is being developed with the potential to address both symptoms and underlying disease mechanisms, positioning the therapy in a large and underserved global market. The anti-inflammatory and tissue regenerative properties of PPS indicate potential application in diseases where inflammation plays a major pathogenic role.
Phase 3 trial design builds on successful PARAOA008 study
The PARAOA012 Phase 3 trial has been designed to closely align with Paradigm’s earlier PARAOA008 study, which demonstrated clinically meaningful improvements in pain and function. The two studies utilise a comparable patient population, the same dosing regimen of injectable pentosan polysulfate sodium, and similar study duration and endpoints.
Maintaining this consistency in trial design is intended to reduce development risk and support comparability across the clinical programme. The strong alignment between the Phase 3 study design and Paradigm’s earlier clinical trials provides continuity that supports regulatory comparability.
| Study Element | PARA_OA_008 | PARA_OA_012 Phase 3 |
|---|---|---|
| Patient Population | Knee osteoarthritis | Comparable cohort |
| Treatment | Injectable PPS | Same dosing regimen |
| Study Duration | Similar timeframe | Day 112 assessment |
| Endpoints | Pain and function | Pain and function |
This deliberate continuity allows investors to draw comparisons between the earlier successful trial and the current Phase 3 programme whilst benefiting from methodological refinements developed through consultation with regulatory agencies.
Key refinements to strengthen data quality
The PARAOA012 protocol incorporates key learnings generated across Paradigm’s earlier clinical studies, including the PARAOA002 dose-ranging study. These learnings have informed refinements to the trial methodology that were developed in consultation with regulatory agencies and leading scientific advisors.
One of the key enhancements relates to the measurement of pain outcomes. The PARAOA012 study utilises weekly average of daily pain recordings as the primary pain endpoint. This approach captures real-time patient pain assessments and reduces recall bias compared with retrospective questionnaires.
The study continues to collect WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) outcomes as secondary endpoints. While WOMAC relies on approximately 48-hour recall of symptoms, the inclusion of daily pain recordings provides an immediate assessment of patient experience and is intended to improve sensitivity in detecting treatment effects.
| Assessment Method | Recall Period | Purpose in PARA_OA_012 |
|---|---|---|
| Daily pain recordings | Real-time | Primary endpoint |
| WOMAC Index | ~48 hours | Secondary endpoint |
These refinements reflect learnings from prior clinical studies and align with contemporary regulatory and scientific guidance regarding approaches to mitigate placebo response and improve data reliability in osteoarthritis trials. Placebo response is a well-recognised challenge in osteoarthritis clinical trials, particularly when relying on retrospective pain assessments.
Timeline to interim analysis and key milestones ahead
Following completion of the Day 112 assessments, the interim dataset will undergo data cleaning and independent DMC statistical analysis, which is expected to take approximately four to six weeks. Based on the current study timeline, Paradigm expects the interim analysis results to be delivered in August 2026.
The interim analysis will assess efficacy and safety in approximately half of the total planned study population, providing an early look at the treatment effect in the study. This represents an important clinical milestone for the programme.
The sequential milestones investors should track are:
- Day 112 assessments completed by interim cohort
- Data cleaning process
- Independent DMC statistical analysis (four to six weeks)
- Interim analysis results (August 2026)
The August 2026 interim readout represents a binary catalyst for the stock. Positive data would validate the Phase 3 programme and potentially de-risk the path toward regulatory submission, whilst also providing the first look at Phase 3 efficacy data from the PARAOA012 trial.
The next major ASX story will hit our subscribers first
Management commentary on Phase 3 progress
Paul Rennie, Managing Director
“Achieving 50% enrolment in the PARAOA012 study represents a significant milestone as we progress toward the interim analysis. The trial design closely mirrors our earlier PARAOA008 study in terms of patient population and dosing regimen, while incorporating important refinements developed in consultation with regulatory agencies and leading scientific advisors.”
Rennie also addressed the methodological improvements incorporated into the trial design, stating that “these improvements, including the use of weekly average of daily pain recordings alongside continued WOMAC assessments, are intended to strengthen the study’s ability to detect clinically meaningful treatment effects while managing placebo response, which is a recognised challenge in osteoarthritis clinical trials.”
The comments provide confidence in execution and highlight the deliberate approach to trial design optimisation. Management’s focus on managing placebo response through improved methodology directly addresses a known failure mode in osteoarthritis trials.
Paradigm will continue to update the market as patients progress through the Day 112 follow-up period and the study advances toward the planned interim analysis. The August 2026 interim results represent the next major inflection point for the programme, with the potential to validate years of clinical development in a market characterised by significant unmet need and limited disease-modifying treatment options.
Want the Next Healthcare Breakthrough in Your Inbox?
Join 20,000+ investors receiving FREE breaking ASX healthcare news within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at StockWire X to get market-moving announcements delivered straight to your inbox the moment they break.